2019
DOI: 10.1096/fasebj.2019.33.1_supplement.646.7
|View full text |Cite
|
Sign up to set email alerts
|

Embryonic Stem Cells Derived Exosomes Enhances Chemosensitivity of Doxorubicin in Breast Cancer Cells

Abstract: Doxorubicin (DOX) is the most effective anti‐tumor agent to treat wide variety of solid tumors, including the breast cancer. However, it is not known whether combination treatment of embryonic stem cells derived exosomes (ES‐exos) with DOX influences the killing of breast cancer cells. To address this question, breast cancer cell lines, MDA‐MB231 and MCF7 were treated with DOX (1mM) ± ES‐exos (5 μg/ml, 10 μg/ml or 20 μg/ml) for 24 and 48 hrs. Cell death was assessed by trypan blue exclusion assay and cell prol… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles